NAVITOR PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.navitorpharma.com
Open-Label of SPN-820 in Adults With Major Depressive Disorder
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Navitor Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06235905
- Locations
- 🇺🇸
Muhammad Saleem Ismail, Rochester, New York, United States
Mass Balance Study of NV-5138 in Healthy Male Subjects.
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]-NV-5138
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Navitor Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05152680
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
Phase 2
Completed
- Conditions
- Treatment Resistant Depression
- Interventions
- Drug: matched placebo
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Navitor Pharmaceuticals, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05066672
- Locations
- 🇺🇸
Northwest Clinical Research Center, Inc., Bellevue, Washington, United States
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Navitor Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03606395
- Locations
- 🇺🇸
Synergy San Diego, San Diego, California, United States
🇺🇸Innovative Clinical Research Inc, Hialeah, Florida, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath